152 related articles for article (PubMed ID: 11973430)
1. TACE/ADAM17-TNF-alpha pathway in rat cortical cultures after exposure to oxygen-glucose deprivation or glutamate.
Hurtado O; Lizasoain I; Fernández-Tomé P; Alvarez-Barrientos A; Leza JC; Lorenzo P; Moro MA
J Cereb Blood Flow Metab; 2002 May; 22(5):576-85. PubMed ID: 11973430
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of TNF-alpha convertase (TACE/ADAM17) after oxygen-glucose deprivation in rat forebrain slices.
Hurtado O; Cárdenas A; Lizasoain I; Boscá L; Leza JC; Lorenzo P; Moro MA
Neuropharmacology; 2001 Jun; 40(8):1094-102. PubMed ID: 11406201
[TBL] [Abstract][Full Text] [Related]
3. In vitro ischemic tolerance involves upregulation of glutamate transport partly mediated by the TACE/ADAM17-tumor necrosis factor-alpha pathway.
Romera C; Hurtado O; Botella SH; Lizasoain I; Cárdenas A; Fernández-Tomé P; Leza JC; Lorenzo P; Moro MA
J Neurosci; 2004 Feb; 24(6):1350-7. PubMed ID: 14960606
[TBL] [Abstract][Full Text] [Related]
4. The increase in TNF-alpha levels is implicated in NF-kappaB activation and inducible nitric oxide synthase expression in brain cortex after immobilization stress.
Madrigal JL; Hurtado O; Moro MA; Lizasoain I; Lorenzo P; Castrillo A; Boscá L; Leza JC
Neuropsychopharmacology; 2002 Feb; 26(2):155-63. PubMed ID: 11790511
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of TACE/ADAM17 after ischemic preconditioning is involved in brain tolerance.
Cárdenas A; Moro MA; Leza JC; O'Shea E; Dávalos A; Castillo J; Lorenzo P; Lizasoain I
J Cereb Blood Flow Metab; 2002 Nov; 22(11):1297-302. PubMed ID: 12439286
[TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate.
Zhang Z; Oliver P; Lancaster JR; Schwarzenberger PO; Joshi MS; Cork J; Kolls JK
FASEB J; 2001 Feb; 15(2):303-5. PubMed ID: 11156944
[TBL] [Abstract][Full Text] [Related]
7. Multiple metalloproteinases process protransforming growth factor-alpha (proTGF-alpha).
Hinkle CL; Mohan MJ; Lin P; Yeung N; Rasmussen F; Milla ME; Moss ML
Biochemistry; 2003 Feb; 42(7):2127-36. PubMed ID: 12590602
[TBL] [Abstract][Full Text] [Related]
8. A new method for detecting TNF-alpha-secreting cells using direct-immunofluorescence surface membrane stainings.
Bueno C; Rodriguez-Caballero A; García-Montero A; Pandiella A; Almeida J; Orfao A
J Immunol Methods; 2002 Jun; 264(1-2):77-87. PubMed ID: 12191512
[TBL] [Abstract][Full Text] [Related]
9. Implication of TNF-alpha convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis.
Colón AL; Menchén LA; Hurtado O; De Cristóbal J; Lizasoain I; Leza JC; Lorenzo P; Moro MA
Cytokine; 2001 Dec; 16(6):220-6. PubMed ID: 11884025
[TBL] [Abstract][Full Text] [Related]
10. Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers.
Gilles S; Zahler S; Welsch U; Sommerhoff CP; Becker BF
Cardiovasc Res; 2003 Dec; 60(3):608-16. PubMed ID: 14659806
[TBL] [Abstract][Full Text] [Related]
11. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase.
Beck G; Bottomley G; Bradshaw D; Brewster M; Broadhurst M; Devos R; Hill C; Johnson W; Kim HJ; Kirtland S; Kneer J; Lad N; Mackenzie R; Martin R; Nixon J; Price G; Rodwell A; Rose F; Tang JP; Walter DS; Wilson K; Worth E
J Pharmacol Exp Ther; 2002 Jul; 302(1):390-6. PubMed ID: 12065742
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
13. Reverse hydroxamate-based selective TACE inhibitors.
Kamei N; Tanaka T; Kawai K; Miyawaki K; Okuyama A; Murakami Y; Arakawa Y; Haino M; Harada T; Shimano M
Bioorg Med Chem Lett; 2004 Jun; 14(11):2897-900. PubMed ID: 15125955
[TBL] [Abstract][Full Text] [Related]
14. Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells.
Kirkegaard T; Pedersen G; Saermark T; Brynskov J
Clin Exp Immunol; 2004 Jan; 135(1):146-53. PubMed ID: 14678276
[TBL] [Abstract][Full Text] [Related]
15. Expression and localization of tumour necrosis factor-alpha and its converting enzyme in human abdominal aortic aneurysm.
Satoh H; Nakamura M; Satoh M; Nakajima T; Izumoto H; Maesawa C; Kawazoe K; Masuda T; Hiramori K
Clin Sci (Lond); 2004 Mar; 106(3):301-6. PubMed ID: 14580234
[TBL] [Abstract][Full Text] [Related]
16. Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.
Holms J; Mast K; Marcotte P; Elmore I; Li J; Pease L; Glaser K; Morgan D; Michaelides M; Davidsen S
Bioorg Med Chem Lett; 2001 Nov; 11(22):2907-10. PubMed ID: 11677124
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of propofol in a model of ischemic cortical cell cultures: role of glutamate and its transporters.
Velly LJ; Guillet BA; Masmejean FM; Nieoullon AL; Bruder NJ; Gouin FM; Pisano PM
Anesthesiology; 2003 Aug; 99(2):368-75. PubMed ID: 12883409
[TBL] [Abstract][Full Text] [Related]
18. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).
Pan B; Farrugia AN; To LB; Findlay DM; Green J; Lynch K; Zannettino AC
J Bone Miner Res; 2004 Jan; 19(1):147-54. PubMed ID: 14753746
[TBL] [Abstract][Full Text] [Related]
19. Effect of TNF-alpha--converting enzyme inhibitor on insulin resistance in fructose-fed rats.
Togashi N; Ura N; Higashiura K; Murakami H; Shimamoto K
Hypertension; 2002 Feb; 39(2 Pt 2):578-80. PubMed ID: 11882611
[TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator protects hippocampal neurons from oxygen-glucose deprivation injury.
Flavin MP; Zhao G
J Neurosci Res; 2001 Mar; 63(5):388-94. PubMed ID: 11223913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
